54 episodes

Independent GI physicians and administrative leaders discuss issues that impact gastroenterology.

Gastro Broadcast Gastro Broadcast

    • Health & Fitness
    • 5.0 • 4 Ratings

Independent GI physicians and administrative leaders discuss issues that impact gastroenterology.

    Episode #54: Bringing Interventional GI into Private Practice (providing care previously available only in the hospital setting)

    Episode #54: Bringing Interventional GI into Private Practice (providing care previously available only in the hospital setting)

    Dr. Michael Weinstein interviews Dr. Prashant Krishnan and Dr. Neil Sharma of Peak Gastroenterology Associates in Colorado about building an interventional gastroenterology practice.

    Peak Gastroenterology is working to deliver interventional endoscopy and endoscopic oncology care to its community, which has historically only been available in larger health systems and academic settings.

    Join Dr. Weinstein, Dr. Krishnan, and Dr. Sharma as they explore some of the barriers to highly specialized medical care in private practice and the potential opportunities to overcome those barriers.

    Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC

    Mixed and mastered by Hayden Margolis

    Gastro Broadcast, Episode 54

    • 22 min
    Episode #53: Using Data and Technology to Improve Patient Care (and support the physicians caring for them)

    Episode #53: Using Data and Technology to Improve Patient Care (and support the physicians caring for them)

    Host Kevin Harlen interviews Sap Sinha, chief operating officer of Allied Digestive Health where he leads its management service organization.

    Allied Digestive Health has multiple locations in New Jersey and New York, with 160 gastroenterologists and more than 200 clinicians. The organization recently partnered with Provation, so that physicians and nurses across its various offices will be able to document patient visits and procedures across any internet-enabled device.

    Another recent partnership with Lynx.MD, a medical data intelligence platform enables the integrated practices to develop, test and validate GI-related treatments and therapies.

    Join Kevin and Sap to hear about how these technology platforms are enabling Allied Digestive Health to enhance operations in its practices and how innovations in technology and data can help improve patient care.

    Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC

    Mixed and mastered by Hayden Margolis

    Gastro Broadcast, Episode 53

    • 27 min
    Episode #52: Be Innovative, Be Agile, and Focus on High-Quality Care (your biggest competitor is the status quo)

    Episode #52: Be Innovative, Be Agile, and Focus on High-Quality Care (your biggest competitor is the status quo)

    Dr. Lisa Mathew interviews Dr. Russ Arjal, who is the co-founder, chief medical officer, and president of Telebelly, a virtual GI clinic offering remote care to patients.

    Telebelly provides nurse practitioners, physician assistants, and medical assistants to support GI practices and their patients.

    Join Dr. Mathews and Dr. Arjal as they explore the future of independent GI and the innovations that will help practices compete and thrive in the future.

    Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC

    Mixed and mastered by Hayden Margolis

    Gastro Broadcast, Episode 52

    • 18 min
    Episode #51: Treating Celiac Disease by Restoring a Healthy Gut Wall (clinical trial on an innovative treatment shows promise)

    Episode #51: Treating Celiac Disease by Restoring a Healthy Gut Wall (clinical trial on an innovative treatment shows promise)

    Dr. Michael Weinstein interviews Dr. Andreas Muehler, chief medical officer of Immunic Therapeutics, which is developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.

    At United European Gastroenterology Week, Immunic presented data from the company’s phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator used to treat celiac disease. Immunic’s new approach to treatment entails restoring a healthy gut wall by modulating SIRT6, a stress responsive protein that helps repair our cells.

    Join Dr. Weinstein and Dr. Muehler as they explore the challenges faced by patients with celiac disease and new innovations that will impact the way physicians treat their patients.

    Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC

    Original score by Hayden Margolis

    Gastro Broadcast, Episode 51

    • 25 min
    Episode #50: Predicting Cancer in Patients with Barrett’s Esophagus (a new test can help GI docs identify who is at greater risk)

    Episode #50: Predicting Cancer in Patients with Barrett’s Esophagus (a new test can help GI docs identify who is at greater risk)

    Patients with Barrett’s Esophagus are at a higher risk to develop esophageal cancer, but it has always been challenging for physicians to determine which of their patients are at greatest risk.

    Dr. Michael Weinstein interviews Dr. Mathew Goldberg, who is medical director of Castle Biosciences about TissueCypher, a test to help gastroenterologists stratify risk for cancer in patients with Barrett's Esophagus.

    Join Dr. Weinstein and Dr. Goldberg to hear about how this innovative test can help gastroenterologists and pathologists better identify those patients who are most at risk and provide the appropriate care to help prevent them from developing esophageal cancer.

    ---

    Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC

    Original score by Hayden Margolis

    • 30 min
    Episode #49: Treating C. diff by Reducing the Associated Inflammation (research shows that it works in mice)

    Episode #49: Treating C. diff by Reducing the Associated Inflammation (research shows that it works in mice)

    Dr. Lisa Mathews interviews Dr. Min Dong and Dr. Meenakshi Rao of the Boston Children’s Hospital regarding new research published in Nature that shows two FDA-approved drugs can alter our body’s own immune response to treat Clostridioides difficile (C. diff) more effectively.

    C. diff is the leading cause of gastrointestinal infections in the United States, and existing medications don’t always work because of antibiotic resistance, the presence of more lethal strains, and a drugs’ potential to harm good gut bacteria that prevent infection.

    The study conducted by Dr. Dong and Dr. Rao found that two already approved medications reduced inflammation associated with C. diff infection in mice, allowing for their immune systems to mount a more productive response to the infection.

    Listen to Dr. Mathew, Dr. Dong, and Dr. Rao as they explore what the next steps are for this research and what it might mean for the future of treating patients with C. diff.

    ---

    Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC

    Original score by Hayden Margolis

    Gastro Broadcast, Episode 49

    • 17 min

Customer Reviews

5.0 out of 5
4 Ratings

4 Ratings

Top Podcasts In Health & Fitness

Huberman Lab
Scicomm Media
ZOE Science & Nutrition
ZOE
The School of Greatness
Lewis Howes
On Purpose with Jay Shetty
iHeartPodcasts
Nothing much happens: bedtime stories to help you sleep
iHeartPodcasts
Passion Struck with John R. Miles
John R. Miles

You Might Also Like

Gastroenterology Learning Network
Gastroenterology Learning Network
American Journal of Gastroenterology Author Podcasts
American College of Gastroenterology
Core IM | Internal Medicine Podcast
Core IM Team
White Coat Investor Podcast
Dr. Jim Dahle of the White Coat Investor
Freakonomics Radio
Freakonomics Radio + Stitcher
The Daily
The New York Times